Cardiovascular risk prediction in HIV-infected patients: Comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) risk prediction models

HIV Medicine

Volumn 17, Issue 4, 2016, Pages 289-297

  Krikke, M ^a   Hoogeveen, Rc ^a   Hoepelman, Aim ^a   Visseren, Flj ^a   Arends, J E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atherosclerotic cardiovascular disease risk score (ASCVD); Cardiovascular disease; Data collection on adverse events of anti HIV drugs (D:A:D); Framingham; HIV infection; Risk prediction; Systematic coronary risk evaluation (SCORE)

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK SCORE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA COLLECTION ON ADVERSE EVENT OF ANTI HUMAN IMMUNODEFICIENCY VIRUS DRUGS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PREDICTION; PRIORITY JOURNAL; SYSTEMATIC CORONARY RISK EVALUATION FOR THE NETHERLANDS; ADOLESCENT; ADVERSE EFFECTS; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; NETHERLANDS; RISK ASSESSMENT; THEORETICAL MODEL; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NETHERLANDS; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

EID: 84961207808     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12300     Document Type: Article

References (47)

1. UNAIDS. UNAIDS report on the global AIDS epidemic | 2012. 2012.
2. Mocroft A, Ledergerber B, Katlama C etal. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
3. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 2008; 22 (Suppl 3): S7-S12.
4. Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J 2013; 34: 3538-3546.
5. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11: 462-468.
6. Freiberg MS, Chang C-CH, Skanderson M etal. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4: 425-432.
7. Kaplan RC, Kingsley LA, Gange SJ etal. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22: 1615-1624.
8. Lichtenstein KA, Armon C, Buchacz K etal. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435-447.
9. van Wijk JPH, Cabezas MC. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med 2012; 2012: 201027.
10. Currier JS, Taylor A, Boyd F etal. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
11. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
12. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart 2009; 95: 1193-1202.
13. Hoyert DL, Ph D, Xu J, Statistics V, 'National vital statistics reports deaths: preliminary data for 2011, ' Natl Vital Stat Rep 2012; 61: 1-51.
14. Lohse N, Hansen AB, Pedersen G etal. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
15. Conroy RM, Pyörälä K, Fitzgerald AP etal. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
17. D'Agostino RB, Vasan RS, Pencina MJ etal. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
18. Goff DC, Lloyd-Jones DM, Bennett G etal. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-2959.
19. Friis-Møller N, Thiébaut R, Reiss P etal. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491-501.
20. Ceccarelli G, D'Ettorre G, Vullo V. The challenge of cardiovascular diseases in HIV-positive patients: it's time for redrawing the maps of cardiovascular risk? Int J Clin Pract 2013; 67: 1-3.
21. Knobel H, Jericó C, Montero M etal. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007; 21: 452-457.
22. Friis-Møller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 2007; 45: 1082-1084.
23. D'Agostino RB. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis 2012; 205 (Suppl 3): S362-S367.
24. Reiner Z, Catapano AL, De Backer G etal. ESC/EAS guidelines for the management of dyslipidaemias. Rev Esp Cardiol 2011; 64: 1168.
25. van Sighem A, Smit C, Holman R etal. van, 'Monitoring report 2012: human immunodeficiency virus (HIV) infection in the Netherlands, ' 2012.
26. van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil 2010; 17: 244-249.
27. van Dis I, Geleijnse JM, Boer JM etal. Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. Eur J Prev Cardiol 2014; 21: 377-383.
28. Moreira Guimarães MM, Bartolomeu Greco D, Ingles Garces AH, de Oliveira AR, Bastos Fóscolo R, de Campos Machado LJ. Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010; 64: 739-745.
29. Nery MW, Martelli CM, Silveira EA etal. Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. Scientificworldjournal 2013; 2013: 969281.
30. Allan GM, Garrison S, McCormack J. Comparison of cardiovascular disease risk calculators. Curr Opin Lipidol 2014; 25: 254-265.
31. Hippisley-Cox J, Coupland C, Vinogradova Y etal. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336: 1475-1482.
32. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004; 47: 2118-2128.
33. European AIDS Clinical Society (EACS). EACS European AIDS clinical society, guidelines V7.0, 2013. Available at http://www.eacsociety.org/files/guidelines-7.1-english.pdf (accessed 21 July 2015).
34. Go AS, Mozaffarian D, Roger VL etal. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292.
35. Parra S, Coll B, Aragonés G etal. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010; 11: 225-231.
36. Schambelan M, Wilson PWF, Yarasheski KE etal. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118: e48-e53.
37. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187.
38. Hense H-W, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937-945.
39. Brindle P, Emberson J, Lampe F etal. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327: 1267.
40. Edwards-Jackson N, Kerr S, Tieu H etal. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med 2011; 12: 510-515.
41. Zeb I, Budoff M. Coronary artery calcium screening: does it perform better than other cardiovascular risk stratification tools? Int J Mol Sci 2015; 16: 6606-6620.
42. Kavousi M, Leening MJ, Nanchen D, etal. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311: 1416-1423.
43. Cook NR, Paynter NP, Eaton CB etal. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation 2012; 125: 1748-1756, S1-11.
44. de Visser CL, Bilo HJG, Thomsen TF, Groenier KH, Meyboom-de Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003; 253: 553-562.
45. Neuhauser HK, Ellert U, Kurth B-M. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. Eur J Cardiovasc Prev Rehabil 2005; 12: 442-450.
46. Scheltens T, Verschuren WMM, Boshuizen HC etal. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. Eur J Cardiovasc Prev Rehabil 2008; 15: 562-566.
47. Al-Lawati JA, Barakat MN, Al-Lawati NA etal. Cardiovascular risk assessment in diabetes mellitus: comparison of the general Framingham risk profile versus the World Health Organization/International Society of Hypertension risk prediction charts in Arabs - clinical implications. Angiology 2013; 64: 336-342.